The course of chronic myeloid leukemia (CML) has changed substantially thanks to the use of a class of drugs called tyrosine kinase inhibitors (TKIs). How these drugs are being used is changing too.

Last year a drug designed to treat patients with severe sepsis was yanked from the market after a large study's results showed no benefit. Guess what...a new study shows that no-longer-available drug may, in fact, offer an effective treatment.

Leukemia is a disease of the blood cells. Acute myeloid leukemia (AML) is seen as an explosion of cancer cells in the bone marrow.

A testing system commonly used to diagnose heart problems and other medical conditions has been recalled by the U.S. Food and Drug Administration.

A lot of medical research may not prove beneficial to patients right away, but all research advances the disease knowledge base. Such is the case with a new study relating to multiple myeloma , a rare blood cancer.

Clot-busting drug tissue plasminogen activator ( tPA ) is the only approved treatment for dissolving blood clots common during stroke, heart attacks or pulmonary embolisms.

Patients with a severe form of aplastic anemia may not see a benefit with traditional therapies. However, a platelet-enhancing drug could be an option for individuals with the rare blood disorder.

The link between cancer and the body's metabolism is a scientific focus that is bearing more fruit. An " oncometabolite " is cancer-causing metabolite that's involved in the development and progression of cancer.

Patients who refuse blood transfusions when undergoing heart surgery do not appear to be at an added risk of complications following the procedure.

Multiple myeloma is a cancer similar to leukemia, where immune system cells in the blood begin to multiply out of control.